| | | Case 1:25-cv-03593 Document 1 Filed 11/02/25 Page 1 of 32
IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MARYLAND
SOUTHERN DIVISION
AURINIA PHARMACEUTICALS INC., and
AURINIA PHARMA U.S., INC.,
Plaintiffs,
v.
Civil Action No.
1:25-cv-3593
___________
JURY TRIAL DEMANDED
GEORGE F. TIDMARSH,
Defendant.
COMPLAINT
Plaintiffs Aurinia Pharmaceuticals Inc. (“Aurinia”) and Aurinia Pharma U.S., Inc.
(“Aurinia US”), for their complaint against Defendant George F. Tidmarsh (“Dr. Tidmarsh”),
allege as follows:
NATURE OF THE ACTION
1. This is an action by Plaintiffs Aurinia and Aurinia US to hold Dr. Tidmarsh
accountable for false and defamatory statements he published about Plaintiffs and the voclosporin
drug they developed, market, and distribute.
2. Dr. Tidmarsh’s false and defamatory statements were the products of his
longstanding personal vendetta against Kevin Tang, who currently serves as Chair of the Board of
Aurinia and manages Tang Capital Partners, LP (“Tang Capital”), an investment fund that is
Aurinia’s largest shareholder. Dr. Tidmarsh’s vendetta against Mr. Tang began in 2019. In
November 2019, due to growing concerns over Dr. Tidmarsh’s management of La Jolla
Pharmaceutical Company (“La Jolla”), Mr. Tang, in his then-capacity as Chair of the Board of La
Jolla, asked Dr. Tidmarsh to resign his position as President, Chief Executive Officer (“CEO”),
storage.courtlistener.com |
|
